Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma
Yuki Shimizu, Kohei Maruyama, Mai Suzuki, Hiroshi Kawachi, Siew‐Kee Low, Tomoko Oh‐hara, Kengo Takeuchi, Naoya Fujita, Satoshi Nagayama, Ryohei Katayama
Topics & Concepts
DabrafenibCancer researchV600EMutationMEK inhibitorMAPK/ERK pathwayTrametinibColorectal cancerMedicineMelanomaBiologyVemurafenibCancerInternal medicineSignal transductionGeneGeneticsMetastatic melanomaMelanoma and MAPK PathwaysHER2/EGFR in Cancer ResearchColorectal Cancer Treatments and Studies